Kornimate/medical-research-clean huggingface dataset:
the bc psychosis program biobank and database for genetic polymorphisms and their associations with psychosis disorder

Conditions: Psychosis; Schizophrenia

Summary: the purpose of this study is to determine if candidate polymorphisms in brain-derived neurotrophic factor (bdnf) and catechol-o-methyl transferase (comt) are predictive of psychosis disorder severity, symptomology, and resolution in patients at bcpp. a secondary objective will be to form a biorepository of blood and saliva samples from patients at bcpp so that further genetic, proteonomic and pharmacogenomic studies may be done to gain insight into the genetic basis of differences in psychosis disorder presentation and manifestation, and differences in response to antipsychotic drug treatment.

this is a population-based, genetic-association, candidate polymorphism study. it will involve a prospective and a retrospective component. a blood draw or saliva sample will be performed during the participant's admission to bcpp, which may occur at any point during the participant's length of stay. when a participant has been deemed 'ready for discharge' by his/her attending psychiatrist at bcpp, a full phenotype will be obtained via retrospective chart review. genetic analyses and determination of protein levels will be performed after chart review. following fulfillment of the primary study objective, the remaining blood and saliva samples will be stored in the biobank over the long-term.

Eligibility criteria:
inclusion criteria: * admission to bcpp. * has provided written informed consent. exclusion criteria: * none.
research into diagnostic and prognostic molecular and imaging biomarkers of ocular disorders associated with neurovascular deregulation: biocor cohort

Conditions: Ocular Rosacea; Pachychoroid Disease

Summary: biocor is an interventional clinical trial whose main objectives are objectif are identify molecular biomarker(s) of ocular rosacea and pachychoroid. endpoints are : correlation between pachychoroidosis (defined by choroidal phenotype parameters in oct and autofluorescence) or the stage of ocular rosacea (rosco(29) definition) and biological markers selected on the basis of preclinical work (animal model) and by unbiased methods (proteomics, metabolomics, meibum lipidomics). the study of circulating, ocular and functional biomarkers would enable us to confirm our hypothesis and identify patients who could benefit from treatments that regulate the ans and/or mineralocorticoid pathways.


Eligibility criteria:
inclusion criteria: * male or female \> 18 years of age, of european origin, with signed ± genetic consent * clear ocular media for oct and autofluorescence imaging * signed consent form * be affiliated to a health insurance scheme * control patients are patients scheduled for cataract surgery or visual assessment. exclusion criteria: * high myopia \> 6d * diabetic retinopathy, hereditary retinal dystrophy, untreated retinal detachment, choroidal ocular tumor, choroidal hemangioma * epithelial or stromal keratopathy other than ocular rosacea * corneal surgery less than 3 months old, keratoplasty * deprived of liberty or under guardianship or curatorship
serum bovine immunoglobulin (sbi) in children and young adults with inflammatory bowel disease (ibd)

Conditions: Inflammatory Bowel Diseases; Ulcerative Colitis; Crohn Disease

Summary: this is a randomized, double-blind placebo controlled study to assess for safety, tolerability and nutritional impact of oral serum bovine immunoglobulin (sbi) on pediatric patients and young adults with inflammatory bowel disease (ibd) as assessed by an increase in serum albumin and other nutritional markers including vitamin d level, pre-albumin, transferrin and iron saturation; and improvement in weight and body mass index. sbi is an animal derived protein isolate from the serum of cows containing \>50% igg. it has been used for patients suffering from irritable bowel syndrome, human immunodeficiency virus enteropathy and antibiotic-associated diarrhea for symptomatic relief of diarrhea with good results and minimal side effects. however its role in ibd has not yet been investigated. the investigators hypothesize that the study product will have a positive nutritional impact along with symptom improvement for pediatric and young adult patients with ibd. the volunteers for our study will have established crohn's disease or ulcerative colitis and will be treated with a daily powder (sbi or placebo) added to their breakfast food (egg, yogurt, or peanut butter are best) for total of 60 days followed by 30 day monitoring period after completion of treatment. the volunteers will be followed by clinic visits and labs on day 0, day 15, day 60 and day 90. there is the potential for the treatment to alter disease activity, a secondary outcome, as assessed by measurement of serum markers of inflammation (esr, crp), fecal calprotectin (validated marker of intestinal inflammation), and clinical indices like short pediatric crohn's disease activity index (shpdcai) or pediatric ulcerative colitis activity index (pucai) for children and harvey bradshaw index or sccai for adults. stool samples will be collected on day 0 and day 60 for 16s rna sequencing to assess for changes in microbiota of the participants while on the study product/placebo. we plan to enroll 43 patients in the study to allow for data analysis of atleast 30 patients. the study will take place over 1 year and will be conducted at university of texas-children's memorial hermann hospital, where we follow \> 125 children with inflammatory bowel disease.


Eligibility criteria:
inclusion criteria: * pediatric patients, ages 6-30 years diagnosed with inflammatory bowel disease (uc/crohn's disease) based on the pediatric ulcerative colitis activity index/ short pediatric crohn's disease activity index for children and harvey bradshaw index/sccai for young adults exclusion criteria: * patients with severe illness requiring inpatient admission * patients with known allergy to beef or beef products, sunflower lecithin and dextrose * patients with liver function tests elevated to more than 3 times the upper limit of normal * pregnancy or breastfeeding

Keywords: serum bovine immunoglobulin
effect of an abdominal hypopressive technique program on pelvic floor muscles and urinary incontinence in women

Conditions: Mild Pelvic Floor Dysfunction

Summary: abdominal hypopressive technique (aht) is a therapy created for the treatment of the pelvic floor dysfunctions in the postpartum. in the last years it has been extended out of such medical context but there is a lack of scientific evidence, and the endurability of the effects of this technique are unknown. the investigator´s aim was to evaluate the effect of a 12 weeks aht program on 1) the tone of the pelvic floor muscles and 2) on urinary incontinence, in women out of the postpartum phase. in addition the investigators looked for the endurability of its effect. methods: the investigators performed a cross-over blinded intervention study of 4 month duration, in which women, stratified by age, were randomly assigned to a sequence of aht-no aht or no aht-aht. the aht program consisted of 30 minute sessions, 3 days per week during 2 months. the investigators compared the effect of aht versus no aht, and of no aht after 2 months versus aht. the endpoints were the differences in perineal tonometry, and urinary incontinence symptoms, as measured by the iciq_sf. comparisons were tested with student t tests, paired or unpaired as adequate.


Eligibility criteria:
inclusion criteria: * no systematic participation in sports or physical activities (≤ 3 sessions per week, ≤ 2 weeks per month) * between 20 and 65 years old * with availability for three afternoons per week. exclusion criteria: * hypertension * serious diseases * pregnancy * postpartum phase up to 2 months after delivery.
outcome of discharged hfmref patients

Conditions: Heart Failure With Mid Range Ejection Fraction

Summary: this study aimed to define the independent risk factors related cardiac events (cardiac death or heart failure-related hospitalization) among heart failure with mildly reduced ejection fraction (hfmref) patients who discharged from the xiangtan central hospital. through the long-term follow-up the cardiovascular outcome of patients being discharged from the hospital, the risk factors related to cardiovascular outcome (cardiac death or heart failure-related hospitalization) will be explored to provide clinical evidence to intervene the discharged hfmref patients aiming to improve patients outcome in the future clinical practice.

this study aimed to define the independent risk factors related cardiac events (cardiac death or heart failure-related hospitalization) among heart failure with mildly reduced ejection fraction (hfmref) patients who hospitalized in xiangtan central hospital from january 1, 2015 to august 31, 2020. the patients would be clinically followed-up until august 31, 2021 per clinical visit or telephone call, the risk factors related to cardiovascular outcome (cardiac death or heart failure-related hospitalization) will be explored to provide clinical evidence to intervene the discharged hfmref patients aiming to improve patients outcome in the future clinical practice. the clinical features of hospitalized heart failure with mildly reduced ejection fraction (hfmref, ef 41-49%) will be analyzed by retrospectively by reviewing patients medical records, laboratory and clinical imaging examination results during initial hospitalization, clinical outcome of enrolled patients will be obtained through clinical visit and telephone call. the primary endpoint is the composite cardiac events (cardiac death or heart failure related rehospitalization). the secondary endpoint is the all-cause death.

Eligibility criteria:
inclusion criteria: * diagnosis: heart failure with mildly reduced ejection fraction (hfmref) presence of symptoms and/or signs of hf, and a mildly reduced lvef (41- 49%); elevated natriuretic peptides (bnp \>35 pg/ml or nt-probnp \>125 pg/ml); other evidence of structural heart disease. exclusion criteria: * none
clinical assessment of arterial dynamic elastance in icu patients, dependent on inotropic or vasopressor drugs.

Conditions: Sepsis; Cardiac Failure Acute

Summary: the primary goal of the study is to determine eadyn ( = ppv/svv) as a functional measure of arterial load, in conjunction with other actual afterload indices, systemic vascular resistance and arterial elastance. a secondary aim is the assessment of the influences of vasopressors and inotropic drugs on eadyn, as a parameter of ventriculo-arterial coupling.

assessment of the cardiovascular status and haemodynamics comprise directly or indirectly cardiac output, which is determined by left ventricular preload, contractility, afterload and heart rate. various haemodynamic monitors have been introduced in anaesthesia and icu practice, providing cardiac output either non-invasively or invasively. the combined use of arterial pressure monitoring with these devices provides insight not only in cardiac output but offers bedside assessment of most determinants of cardiovascular function. both pulse pressure variation (ppv) and stroke volume variation (svv) have been described as dynamic descriptors of fluid responsiveness, a measure allowing optimization of preloading conditions if haemodynamics show signals of insufficient perfusion. arterial load can be assessed based on a two-element windkessel model with a static and dynamic component. the static part consists of a resistive element (systemic vascular resistance: svr = (map/c0)\*80, with map, mean arterial pressure; co, cardiac output) and a pulsatile component (net arterial compliance c = sv/arterial pulse pressure with sv, stroke volume). arterial elastance is considered being an integrative variable, associating both steady elements and heart rate (ea = .9\*sap/sv with ea, arterial elastance; sap, systolic arterial pressure). the dynamic component eadyn is the ratio of ppv and svv during a mechanical ventilator cycle, providing a functional assessment of ventriculo-arterial coupling. combined use of arterial pressure tracing (or its non-invasive surrogate) and (non-) invasive stroke volume actually may provide an interesting framework for haemodynamic monitoring and subsequent optimization in many surgical, postoperative or icu patients. this study aims to copy as good as possible the handling and the way of management as in a clinical setting.

Eligibility criteria:
inclusion criteria: - icu patients, treated/supported with noradrenalin or dobutamine. exclusion criteria: * septic shock * aortic valve regurgitation and defect of septum * severe aortic sclerosis, aortic prosthesis * severe hypertension (map \> 130 mmhg) * cardiac arrhythmia * tachycardia with a heart rate higher than 150 bpm * age below 18 or above 75 y * patient height below 120 cm (48") or above 230 cm (90") * patient weight less than 30 kg (67 lbs.) or greater than 155 kg (341 lbs.) * intra-aortic balloon pump

Keywords: vasoactive medication dynamic arterial elastance
ultrasound guided serratus anterior plane block versus thoracic erector spinae plane block for post operative analgesia in pediatrics undergoing thoracotomy

Conditions: Ultrasound; Serratus Anterior Plane Block; Thoracic Erector Spinae Plane Block; Post Operative Analgesia; Pediatrics; Thoracotomy

Summary: this study is designed to compare the post operative analgesic effect of serratus anterior plane block versus thoracic erector spinae plane block in pediatrics undergoing thoracotomy

the incidence of diseases that requires thoracotomy is low in the pediatric age group. thoracotomy is a severe burden on children and is widely known to cause severe acute pain. this pain can be very distressing for both children and their parents. if not treated properly, it may acutely cause retention of secretion, atelectasis, ventilation-perfusion disorder and hypoxemia, together with a change in lung mechanics. the serratus anterior plane block (sapb) has also recently become more popular options for post-thoracotomy analgesia. sapb involves local anesthetic injection in a plane superficial or deep to the serratus anterior muscle; in both these locations, it blocks the lateral cutaneous branches of intercostal nerves. the erector spinae plane block (espb) is an ultrasound-guided deep plane interfascial block defined by forero in 2016. it has been shown to provide thoracic and abdominal analgesia. when injected at the t5 transverse process level, the local anesthetic spreads anteriorly through the thoracolumbar fascia and reaches the ventral and dorsal rami of the spinal nerves and posteriorly to the gray and white rami communicantes of the sympathetic chain, providing a c7 to t8 sensitive block. although it was first described as a chronic pain block, there are increasingly reports about its use in postoperative acute pain.

Eligibility criteria:
inclusion criteria: * patient aged between 2 and 7 years. * patient posted for the right or left thoracotomy under general anesthesia. exclusion criteria: * parents who refuse regional anesthesia. * children who had any coagulation abnormality. * deformity of the thoracolumbar spine. * infection at the site of injection. * history of allergy to the local anesthetics.
the role of glucose-dependent insulinotropic polypeptide in the pathological glucose homeostasis of type 1 diabetes

Conditions: Diabetes Mellitus, Type 1; Hypoglycemia

Summary: in the present project the investigators will evaluate whether glucagonotropic properties of the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (gip) may be utilized as a safeguard against hypoglycemia in the daily life of participants with type 1 diabetes


Eligibility criteria:
inclusion criteria: * body mass index between 20 and 27 kg/m2 * t1d (diagnosed according to the criteria of the world health organization) with hba1c \<69 mmol/mol (\<8.5%) * treatment with a stable insulin regimen ≥3 months * t1d duration between 2 and 15years * c-peptide negative (c-peptide ≤ 16 ng/ml) * informed consent exclusion criteria: * anemia (hemoglobin outside normal range) * known liver disease and/or alat and/or asat \> 2 times normal values * estimated glomerular filtration rate (egfr) ≤60 ml/min/1.73 m2 or albuminuria * prior cardiovascular events and/or abnormal heart rate/blood pressure * use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to randomization * any physical or psychological condition that the investigator feels would interfere with trial participation

Keywords: gastric inhibitory polypeptide diabetes mellitus, type 1 hypoglycemia glucose metabolism disorders metabolic diseases endocrine system diseases glucagon incretin
safety, tolerance and antiretroviral activity of dasatinib: a pilot clinical trial in patients with recent hiv-1 infection

Conditions: Recent HIV-1 Infection

Summary: study to evaluate the safety, tolerability and antiretroviral activity of a new therapeutic strategy, based on the administration of dasatinib, an itk, in patients with recent (3-12 months) asymptomatic hiv-1 infection.


Eligibility criteria:
inclusion criteria: * 18 to 65 years. * documented asymptomatic hiv-1 infection of 3-12 months duration (all patients must have a positive western blot, including the p31 band whose appearance indicates infection of more than 90 days duration). * not having received art * cd4 t-lymphocyte count\> 350 / μl * patient giving written informed consent exclusion criteria: * active hbv (hbsag+ or dna+) and/or hcv (rna+) infection in screening. * alt\> 2 unl, glomerular filtration rate \<70 ml / 1.73 m2, leukocytes \<4000 / mm3, total lymphocyte count \<1000 / mm3, platelets \<100,000 / mm3 or hg \<12g / dl. * pregnancy or active breastfeeding * ongoing or previous pleural effusion * chronic obstructive pulmonary disease, bronchial asthma or recent chest trauma. * history of gastrointestinal or other bleeding. * any concomitant treatment with potentially dangerous drug interaction with dasatinib. * any clinical condition, at the opinion of the investigator, contraindicating participation (for example, * active neoplastic disease, active concomitant infection, etc.)
gastroesophageal reflux disease in the dutch population

Conditions: Gastro Esophageal Reflux

Summary: rationale: screening for esophageal adenocarcinoma (eac) precursors and treating them may help to decrease mortality of this malignancy. to understand the size of the target population for potential eac screening, insight in the prevalence of registered and unregistered individuals with gastro-esophageal reflux disease (gerd) symptoms is needed. insight in public awareness of eac will provide additional useful information for public communication strategies. objective: the aims of this study are to assess the prevalence of gerd symptoms and related help-seeking behavior, registered and unregistered medication use and awareness of esophageal cancer in the general dutch population. study design: cross-sectional population-based survey. study population: dutch citizens aged 18-75 years. methods: eligible individuals will be selected from the dutch population registry (brp) using simple random sampling. invitations will be sent by postal mail with participants being directed to a digital survey. main study parameters/endpoints: the outcome variables are presence of current gerd symptoms, number of gerd patients that consulted a doctor, number of gerd patients using prescribed and/or over the counter (otc) antacids, histamine-receptor antagonists (h2ras) and proton pump inhibitors (ppis), and awareness and beliefs about esophageal cancer. the association between socio-demographic background and outcome variables will also be evaluated. nature and extent of the burden and risks associated with participation, benefit and group relatedness: subjects will not directly benefit from participating in this study. nonetheless, participating in this study is not associated with any healthcare risks and the burden for the subjects is very low. the survey has a low burdensome nature and will take approximately 20 minutes to complete. all data will be pseudonymized, refusal to fill out the survey or desire to withdraw from the study will not have any consequences for the invited subject.


Eligibility criteria:
inclusion criteria: * age 18 - 75 years exclusion criteria: * unable to provide informed consent for any reason; * unable to fill out the digital survey for any reason.
prospective cohort study of robotic assisted laparoscopic sacrocolpopexy using mpathy restorelle mesh

Conditions: Pelvic Organ Prolapse; Urinary Incontinence; Mesh Erosion

Summary: robotic approach to sacral colpopexy is a relatively new procedure. the literature is scarce in regard to long term outcome. this advanced procedure is offered at morristown memorial. this protocol will review the one year outcome of patients who underwent this procedure using a polypropylene mesh. these outcomes will include anatomical and quality of life measures.


Eligibility criteria:
inclusion criteria: * any patient receiving robotic assisted laparoscopic sacral colpopexy with polypropylene mesh exclusion criteria: * other graft material than polypropylene mesh * enrollment in another study

Keywords: uterine prolapse vaginal prolapse mesh erosion urinary incontinence bowel symptoms